Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir
Open Access
- 24 May 2022
- journal article
- research article
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 30, 101283
Abstract
No abstract availableKeywords
Funding Information
- University of California, San Diego
This publication has 46 references indexed in Scilit:
- Efficacy and safety of telaprevir, a new protease inhibitor, for difficult‐to‐treat patients with genotype 1 chronic hepatitis CJournal of Viral Hepatitis, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Effects of Microtubule Modulators on HIV-1 Infection of Transformed and Resting CD4 T CellsJournal of Virology, 2011
- Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virusHepatology, 2010
- Drug interactions and the evolution of antibiotic resistanceNature Reviews Microbiology, 2009
- Initiation of Hepatitis C Virus Infection Requires the Dynamic Microtubule NetworkJournal of Biological Chemistry, 2009
- Synergy of a Hepatitis C Virus (HCV) NS4A Antagonist in Combination with HCV Protease and Polymerase InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Synergy of Small Molecular Inhibitors of Hepatitis C Virus Replication Directed at Multiple Viral TargetsJournal of Virology, 2007
- Persistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus andHostJournal of Virology, 2006
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005